Floatz logo

Solu-Cortef

Mucopolysaccharidosis II

Joanne Kurtzberg, MDPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Mucopolysaccharidosis II cohort.

Asset / SponsorPhaseRating
PABINAFUSP ALFA
JCR Pharmaceuticals Co., Ltd.
Phase 3BBB
Tividenofusp Alfa
Denali Therapeutics Inc.
Phase 2/3BB
gc1111
Green Cross Corporation
Phase 1/2B
Genotropin
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 2/3B
Idursulfase Beta
Green Cross Corporation
Phase 2CCC

View all 18 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →